12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Company News  |  Deals

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary will acquire Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101. Elevation is also eligible for up to $30 million in milestones tied to development...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >